Connor Clark & Lunn Investment Management Ltd. Makes New $10.93 Million Investment in Kura Oncology, Inc. $KURA

Connor Clark & Lunn Investment Management Ltd. purchased a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, Holdings Channel reports. The fund purchased 996,114 shares of the company’s stock, valued at approximately $10,927,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Ieq Capital LLC purchased a new position in Kura Oncology in the second quarter worth $3,819,000. Allworth Financial LP purchased a new stake in Kura Oncology during the second quarter valued at about $113,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the second quarter worth about $132,000. Great Lakes Advisors LLC bought a new stake in Kura Oncology during the second quarter worth about $2,851,000. Finally, BlackRock Inc. purchased a new position in shares of Kura Oncology in the 2nd quarter worth about $115,286,000.

Kura Oncology Stock Performance

NASDAQ KURA opened at $13.06 on Thursday. The company has a 50-day simple moving average of $10.74 and a two-hundred day simple moving average of $9.58. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology, Inc. has a 12-month low of $7.36 and a 12-month high of $13.90. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -3.88 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, equities analysts forecast that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Troy Edward Wilson acquired 100,000 shares of the stock in a transaction on Monday, August 24th. The stock was bought at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the transaction, the chief executive officer directly owned 479,194 shares of the company’s stock, valued at approximately $5,937,213.66. The trade was a 26.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is owned by insiders.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
• Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
• Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
• Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
• Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
• Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale

Analysts Set New Price Targets

Several equities analysts have recently commented on KURA shares. Morgan Stanley set a $24.00 price objective on Kura Oncology in a research report on Monday. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Raymond James Financial set a $24.00 target price on Kura Oncology in a research note on Monday. Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $25.40.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.